These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37833562)

  • 21. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
    Urso L; Cavallari I; Sharova E; Ciccarese F; Pasello G; Ciminale V
    Br J Cancer; 2020 Jan; 122(1):52-61. PubMed ID: 31819191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADP sensitizes ZL55 cells to the activity of cisplatin.
    Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
    J Cell Physiol; 2019 Apr; 234(4):4409-4417. PubMed ID: 30144378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
    Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
    Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
    Manente AG; Pinton G; Zonca S; Cilli M; Rinaldi M; Daga A; Nilsson S; Moro L
    Oncotarget; 2015 Sep; 6(28):25121-34. PubMed ID: 26208479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
    Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of epigenetics in malignant pleural mesothelioma.
    Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
    Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
    Li Q; Wang W; Machino Y; Yamada T; Kita K; Oshima M; Sekido Y; Tsuchiya M; Suzuki Y; Nan-Ya K; Iida S; Nakamura K; Iwakiri S; Itoi K; Yano S
    Cancer Sci; 2015 Jan; 106(1):102-7. PubMed ID: 25421609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
    Kang Y; Ding M; Tian G; Guo H; Wan Y; Yao Z; Li B; Lin D
    Oncol Rep; 2013 Jul; 30(1):313-9. PubMed ID: 23624653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
    Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
    Truini A; Coco S; Genova C; Mora M; Dal Bello MG; Vanni I; Alama A; Rijavec E; Barletta G; Biello F; Maggioni C; Grossi F
    Microrna; 2016; 5(1):12-18. PubMed ID: 26817512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
    BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.